A strong predictor of full treatment response, CD163 was found to be the most significant urinary protein differentiator between responders and non-responders (median 1.8 pg/mgCr vs. 8.2 pg/mgCr, p = 4e-7) in LN patients in the Belimumab International Systemic Lupus Erythematosus-Lupus Nephritis trial (Weeding et al., 2022). This evidence concerns the gene CD163 and lobular neoplasia.